ASPE ISSUE BRIEF CONTINUING PROGRESS ON THE OPIOID EPIDEMIC: THE ROLE OF THE AFFORDABLE CARE ACT January 11, 2017 The United States is experiencing an unprecedented epidemic of opioid use disorder and overdose. In 2015, more than 33,000 Americans died of an overdose involving a prescription or illicit opioid, and more than 2 million individuals had an opioid use disorder. In partnership with state and local governments, healthcare professionals, and other key stakeholders, HHS launched its Opioid Initiative in March 2015 and has taken significant steps to: 1) improve opioid prescribing practices; 2) increase the use of naloxone to reverse opioid overdoses; and 3) expand access to and the provision of medication-assisted treatment with methadone, buprenorphine, or naltrexone – in combination with appropriate psychosocial services.1 The Department has also continued to prioritize reducing stigma and advancing prevention, treatment, and parity for people needing care for mental health and substance use disorders. The success of these strategies – especially the third – rests on a base of health insurance coverage. What that means is that our nation’s best shot at reversing the opioid epidemic and providing needed care for opioid use disorders, others substance use disorders, and mental illness depends on the continued success of the Affordable Care Act (ACA). Key Findings The share of hospitalizations for substance use or mental health disorders in which the patient was uninsured fell from 22 percent in the fourth quarter of 2013 (just before the ACA’s major coverage provisions took effect) to about 14 percent by the end of 2014. o In states that expanded Medicaid under the ACA, the uninsured share of substance use or mental health disorder hospitalizations fell from about 20 percent in the fourth quarter of 2013 to about 5 percent by mid-2015. Between 2010 and 2015, the share of people foregoing mental health care due to cost has fallen by about one-third for people below 400 percent of the federal poverty level. The states with the highest drug overdose deaths also are projected to experience dramatic increases in their uninsured rates if the ACA were repealed:  The top three – West Virginia, New Hampshire, and Kentucky – would see their uninsured rates nearly or more than triple if the ACA were repealed, as would Massachusetts. ASPE Issue Brief Page 2 Increasing coverage, access to care Over 20 million Americans have gained coverage as a result of the ACA, driving the share of Americans without health insurance to the lowest level in history.2,3 Among those gaining coverage have been millions of Americans who need treatment for opioid use disorders, other substance use disorders, or other behavioral health conditions. Evidence suggests this coverage expansion has improved access to care and outcomes for Americans with opioid or other substance use or mental health disorders. For example, hospitalization data provide strong evidence of substantial coverage gains. Figure 1a. shows that, across all states for which data are available, the share of hospitalizations for substance use or mental health disorders in which the patient was uninsured fell from 22 percent just before the ACA’s major coverage provisions took effect in 2014 to about 14 percent by the end of 2014. For the subset of 17 states for which data are available through the third quarter of 2015 (2015- Q3), the uninsured share fell from 21 percent at the end of 2013 to 11 percent in 2015-Q3, as shown in Figure 1b. These coverage gains were especially pronounced in states that expanded Medicaid under the ACA. Across all Medicaid expansion states for which data are available, the uninsured share of substance use or mental health disorder hospitalizations plummeted from about 20 percent in 2013 to around 6 percent by the end of 2014. For the 10 Medicaid expansion states with data available through the third quarter of 2015, the uninsured share fell from 20 percent at the end of 2013 to about 5 percent in 2015-Q3. January 11, 2017 ASPE Issue Brief Page 3 Figure 1a. Adult Uninsured Hospitalizations as a Share of Total Hospitalizations for Substance Abuse/Mental Health Disorders, 2008-2014 30% 25% 20% 15% 10% 5% 0% 2008 2008 2009 2009 2010 2010 2011 2011 2012 2012 2013 2013 2014 2014 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Expanded Medicaid as of 2015 Had not expanded Medicaid as of 2015 All states with available data Source: HHS analysis of the Healthcare Cost and Utilization Project (HCUP) Fast Stats4, 2016. Notes: The vertical line indicates the final quarter prior to the January 1, 2014, date on which Marketplace coverage took effect and Medicaid expansion took effect in adopting states. States included here with different expansion dates are: MN (March 2010), CA (November 2010), WA (January 2011), NJ (April 2011), CO (April 2012), MO (July 2012), and MI (April 2014). For each group of states (expansion, non-expansion, and all), the share of uninsured hospitalizations in all hospitalizations was calculated as an average of individual states’ percentages of uninsured hospitalizations. This analysis includes states for which complete data are available through 2014. Included as Medicaid-expansion states are: AR, AZ, CA, CO, HI, IL, IA, KY, MA, MD, MI, MN, NJ, NM, NY, NV, OR, RI, VT, WA, and WV. Included as non-expansion states are: FL, GA, IN, KS, LA, ME, MO, MT, NC, NE, OK, PA, SC, SD, TN, TX, UT, VA, WI, and WY. Data for MT begin in 2009. January 11, 2017 ASPE Issue Brief Page 4 Figure 1b. Adult Uninsured Hospitalizations as a Share of Total Hospitalizations for Substance Abuse/Mental Health Disorders, Subset of States with 2008-2015 Q3 Data 30% 25% 20% 15% 10% 5% 0% 2008 2008 2009 2009 2010 2010 2011 2011 2012 2012 2013 2013 2014 2014 2015 2015 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Expanded Medicaid as of 2015 Had not expanded Medicaid as of 2015 All states with available data Notes: The vertical line indicates the final quarter prior to the January 1, 2014, date on which Marketplace coverage took effect and Medicaid expansion took effect in adopting states. States included here with different expansion dates are: MN (March 2010), CA (November 2010), NJ (April 2011), CO (April 2012), MO (July 2012), and MI (April 2014). For each group of states (expansion, non-expansion, and all), the share of uninsured hospitalizations in all hospitalizations was calculated as an average of individual states’ percentages of uninsured hospitalizations. This analysis includes states for which complete data are available through 2015-Q3. Included as Medicaid-expansion states are: CA, CO, HI, IA, KY, MI, MN, NJ, NY, and OR. Included as non-expansion states are: FL, GA, MO, SD, TX, VA, and WI. The same trends have occurred in the states that have been most affected by the opioid epidemic (see Appendix). For example, in West Virginia, the state with the highest drug overdose death rate in 2015, according to Centers for Disease Control and Prevention (CDC) data, the uninsured share of substance use and mental health disorder hospitalizations fell from 23 percent at the end of 2013 to 5 percent at the end of 2014. These data are consistent with other evidence that the ACA’s coverage expansions have been especially important to people with substance use disorders and other behavioral health conditions. For example, ASPE previously estimated that, if additional states chose to expand Medicaid, almost 30 percent5 of those who could gain coverage have a substance use or mental health disorder. ASPE also recently estimated6 that mental health disorders are among the most common pre-existing health conditions for which Americans might have been denied coverage or charged more for coverage prior to ACA. The ACA also ensures that, when people with behavioral health needs gain insurance, their treatment is covered. Prior to the ACA, an estimated 34 percent7 of individual market policies January 11, 2017 ASPE Issue Brief Page 5 did not cover substance use treatment, and an estimated 18 percent8 did not cover treatment for mental health conditions. Today, all coverage is required to include these essential health benefits. Further, because of the ACA and the Mental Health Parity and Addiction Equity Act (MHPAEA), coverage is required to include substance use or mental health disorder benefits. How Coverage Affects Treatment for Opioid Use Disorder Despite ample evidence demonstrating the effectiveness of medication-assisted treatment for people with opioid use disorder, the overwhelming majority of people who need treatment do not get it. Some of the main barriers to treatment are related to cost9, insurance coverage10, and availability. Over the past several years, HHS has worked with state and local governments and the provider community to expand treatment capacity11,12,13 for opioid and other substance use disorders. In addition, through funding included in the21st Century Cures Act, HHS will award close to $1 billion dollars over the next two years to substantially expand state and local capacity to provide medication-assisted treatment and other services to support people with opioid use disorders. But even when capacity exists, patients must still be able to afford the treatment they need. Research14 shows that health insurance coverage makes care more affordable, secure, and reliable15, and people with insurance are more likely to get timely care and have a usual source of care. Nowhere is this more important than for people with an opioid use disorder or other substance use disorder. For these individuals, timely and affordable access to evidence-based treatment, including medication-assisted treatment can be life-saving. Moreover, a large proportion of people with opioid use disorder are also coping with co- occurring mental illness16, most frequently depression and anxiety17, as well as with significant physical health needs18. Appropriate treatment of these co-occurring conditions is often critical to supporting an individual’s long-term recovery from opioid use disorder. With the ACA’s Marketplace and Medicaid expansion entering their fourth year, evidence is mounting19 that they are making a difference in helping people access care, including behavioral health care. For example:  As shown in Figure 2, the share of people foregoing mental health care due to cost has fallen by 33 percent for people with incomes below 138 percent of the poverty level and by 31 percent for people with incomes above 138 and below 400 percent of the federal poverty level. These populations are eligible for the ACA’s Medicaid expansion or tax credits. January 11, 2017 ASPE Issue Brief Page 6  Among low-income adults, Medicaid expansion was associated with a 7.5 percent20 reduction in unmet need for mental health treatment and an 18.3 percent21 reduction in unmet need for substance use disorder treatment services.  Medicaid expansion in Ohio led to especially large improvements22 in access to care and financial security for expansion enrollees with opioid use disorder. 75 percent reported improved overall access to care, 83 percent reported improved access to prescription medications, and 59 percent reported improved access to mental health care.  Medicaid expansion in Kentucky was linked to a large increase23 in Kentuckians receiving treatment for substance use disorder. Parity for mental health and substance use treatment has also resulted in improved access to care. Researchers found that implementation of state-level parity laws prior to the ACA increased the treatment rate for substance use disorders by 9 percent24 among all specialty treatment facilities and by 15 percent25 among treatment facilities accepting private insurance. Under the ACA, these types of parity protections have been expanded and strengthened. Figure 2. Share of People Foregoing Mental Health Care Due to Cost 2010 2015 7.0% 33% Reduction 6.0% 6.0% 5.0% 4.0% 31% Reduction 4.0% 3.5% 3.0% 2.4% 2.0% 1.0% 0.0% ≤ 138% Fed Pov Level (potentially eligible for 138%-400% Fed Pov Level (potentially eligible Medicaid Expansion) for Marketplace subsidies) Source: ASPE analysis of National Health Interview Survey data, 2016. January 11, 2017 ASPE Issue Brief Page 7 In addition to directly addressing access and unmet need for patients, insurance expansion is motivating providers to provide treatment. A recent study26 found that states that made an early commitment to expand Medicaid and establish insurance Marketplaces had significantly higher growth in the number of physicians with a waiver to prescribe buprenorphine for opioid use disorder treatment. This represents a critical first step to expanding access to MAT for people with opioid use disorders. A number of states are also building on Medicaid expansion and taking advantage of other opportunities provided by the ACA to create innovative models of coverage and care for people with opioid use disorders. For example, Maryland, Rhode Island, and Vermont are using variations of the Health Home model to provide comprehensive care management, care coordination, health promotion, comprehensive transitional care/follow-up, individual and family support, and referral to community and social support services. These types of care coordination models are feasible and affordable for states that have expanded Medicaid because most low- income adults with behavioral health needs now have access to comprehensive health coverage, thanks to the ACA’s Medicaid expansion. The models, which have now been implemented for several years, are significantly improving access to and coordination of care for people with opioid use disorders, and other substance use and mental health disorders27. What’s at Stake in the ACA for the Parts of the Country Most Affected by Opioid Use Disorder and Overdoses While the opioid epidemic has affected all parts of the country, some areas have been hit especially hard. The states that have been hit the hardest include many of the states that would be most affected if the ACA coverage gains were rolled back. According to Urban Institute estimates28, four states – Massachusetts, West Virginia, Kentucky, and New Hampshire – would see their uninsured rates nearly or more than triple if the ACA were repealed. These four states ranked 7th, 1st, 3rd, and 2nd respectively in drug overdose death rates in 2015, according to CDC data29. Among the remaining seven states with drug overdose rates exceeding 22 deaths per 100,000 people, uninsured rates would increase by 155 percent (Ohio), 170 percent (Rhode Island), 134 percent (Pennsylvania), 136 percent (New Mexico), 83 percent (Utah), 79 percent (Tennessee), and 124 percent (Connecticut). As the maps (Figure 3 and Figure 4) below show, this pattern holds more broadly: many of the states most affected by drug overdose are also among the states with the most to lose if insurance coverage and associated protections under the ACA were rolled back. For the reasons discussed above, large spikes in uninsured rates could substantially worsen the opioid crisis at a time when the emergence of illicitly made fentanyl and other highly potent synthetic opioids linked to large clusters of overdoses is rapidly increasing in communities across the U.S. January 11, 2017 ASPE Issue Brief Page 8 Figure 3. Drug Overdose Deaths Per 100,000 Population Figure 4. Estimated Increase in Uninsured Population , U.S., 2015 from ACA Repeal Source: CDC, National Vital Statistics System, 2016 Source: Urban Institute, 2016 The opioid epidemic is a public health crisis that will not be reversed overnight. But we are starting to see real progress at all levels of government and among communities across our nation, thanks to a shared commitment to stem the tide of the opioid epidemic. Continued insurance coverage is essential to our ability to be successful, and the crisis is far too urgent to risk undermining our progress. ASPE Issue Brief Page 9 APPENDIX: State-Level Changes in Adult Uninsured Hospitalizations for Substance Use and Mental Health Disorders, by Drug Overdose Death Rate 2015 Age- Adult % Change: Adjusted Uninsured 2013-Q4 Drug Over- Substance Thru Most dose Death Use/ Mental Recent Rate (per Health Available State 100, 000) Hospital Stays Data 2013 Q1 2013 Q2 2013 Q3 2013 Q4 2014 Q1 2014 Q2 2014 Q3 2014 Q4 2015 Q1 2015 Q2 2015 Q3 2015 Q4 2016 Q1 Number of Stays -78.6% 550 650 650 700 150 150 100 150 N/A N/A N/A N/A N/A WV 41.5 Share of Total SU/MH Stays -78.6% 19.3% 21.3% 21.3% 23.3% 5.2% 5.0% 3.1% 5.0% N/A N/A N/A N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A NH 34.3 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Number -86.1% 1700 1900 2000 1800 650 350 350 250 250 250 250 N/A N/A KY 29.9 Share -88.8% 31.8% 33.0% 34.8% 34.6% 12.4% 6.1% 6.0% 4.5% 4.5% 4.2% 3.9% N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A OH 29.9 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Number -75.0% 300 400 400 400 150 100 100 100 N/A N/A N/A N/A N/A RI 28.2 Share -78.6% 15.8% 21.6% 21.1% 22.2% 7.3% 4.7% 4.7% 4.8% N/A N/A N/A N/A N/A Number -16.7% 1650 1700 1800 1800 1500 1400 1400 1500 N/A N/A N/A N/A N/A PA 26.3 Share -19.2% 9.5% 9.4% 9.5% 10.3% 8.7% 7.6% 7.6% 8.3% N/A N/A N/A N/A N/A Number -76.2% 950 1100 1200 1050 450 300 250 250 N/A N/A N/A N/A N/A MA 25.7 Share -78.0% 9.6% 10.7% 11.5% 10.6% 4.4% 2.8% 2.3% 2.3% N/A N/A N/A N/A N/A Number -72.7% 600 600 600 550 350 200 200 150 N/A N/A N/A N/A N/A NM 25.3 Share -69.3% 30.8% 30.0% 29.3% 30.6% 23.3% 12.9% 11.1% 9.4% N/A N/A N/A N/A N/A Number -6.7% 700 700 750 750 700 750 700 700 N/A N/A N/A N/A N/A UT 23.4 Share -11.6% 26.4% 25.9% 25.9% 27.8% 25.0% 25.4% 22.6% 24.6% N/A N/A N/A N/A N/A Number -9.1% 1050 1150 1100 1100 1050 1100 1100 1000 N/A N/A N/A N/A N/A TN 22.2 Share 0.0% 14.7% 15.9% 15.6% 16.7% 17.5% 17.7% 17.3% 16.7% N/A N/A N/A N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A CT 22.1 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A DE 22 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A ASPE Issue Brief Page 10 2015 Age- Adult % Change: Adjusted Uninsured 2013-Q4 Drug Over- Substance Thru Most dose Death Use/ Mental Recent Rate (per Health Available State 100, 000) Hospital Stays Data 2013 Q1 2013 Q2 2013 Q3 2013 Q4 2014 Q1 2014 Q2 2014 Q3 2014 Q4 2015 Q1 2015 Q2 2015 Q3 2015 Q4 2016 Q1 Number 11.1% 450 450 500 450 500 500 600 500 N/A N/A N/A N/A N/A ME 21.2 Share 18.1% 25.7% 25.7% 29.4% 26.5% 32.3% 30.3% 36.4% 31.3% N/A N/A N/A N/A N/A Number -69.4% 2450 2550 2600 2450 950 850 850 750 N/A N/A N/A N/A N/A MD 20.9 Share -69.4% 27.7% 27.9% 27.8% 27.8% 10.7% 9.3% 9.2% 8.5% N/A N/A N/A N/A N/A Number -78.6% 700 700 800 700 700 250 250 200 150 150 150 N/A N/A MI 20.4 Share -80.2% 9.0% 8.4% 9.3% 8.6% 9.2% 3.0% 2.8% 2.4% 1.9% 1.7% 1.7% N/A N/A Number -57.1% 300 350 400 350 200 200 150 150 N/A N/A N/A N/A N/A NV 20.4 Share -64.9% 22.2% 24.1% 26.7% 25.9% 14.3% 12.5% 9.1% 9.1% N/A N/A N/A N/A N/A Number -47.2% 1950 1950 2000 1800 1800 1850 1700 1600 1500 950 N/A N/A N/A IN 19.5 Share -49.7% 26.0% 25.5% 25.5% 25.0% 24.3% 24.3% 21.0% 21.1% 20.3% 12.6% N/A N/A N/A Number -77.8% 850 900 900 900 450 400 300 250 200 200 N/A N/A N/A AZ 19 Share -76.6% 21.8% 21.7% 22.2% 22.2% 10.8% 10.8% 8.1% 7.1% 5.6% 5.2% N/A N/A N/A Number 40.0% 1400 1550 1750 1500 1650 1750 1900 2100 N/A N/A N/A N/A N/A LA 19 Share 17.3% 27.2% 28.7% 32.1% 30.6% 31.1% 31.5% 35.5% 35.9% N/A N/A N/A N/A N/A Number -9.1% 650 700 700 550 550 500 550 500 N/A N/A N/A N/A N/A OK 19 Share -5.1% 17.8% 18.9% 17.9% 15.5% 16.2% 14.7% 14.9% 14.7% N/A N/A N/A N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A DC 18.6 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Number -13.7% 3350 3600 3750 3650 3750 3950 4000 3450 3350 3450 3300 3450 3150 MO 17.9 Share -19.6% 28.8% 28.8% 30.2% 31.7% 31.8% 31.1% 30.5% 28.5% 27.8% 27.4% 26.0% 27.5% 25.5% Number 0.0% 50 50 50 50 50 N/A N/A N/A N/A N/A N/A N/A N/A VT 16.7 Share 11.1% 10.0% 9.1% 9.1% 10.0% 11.1% N/A N/A N/A N/A N/A N/A N/A N/A Number 0.0% 250 200 200 150 150 200 200 150 N/A N/A N/A N/A N/A WY 16.4 Share 0.0% 55.6% 44.4% 44.4% 42.9% 37.5% 40.0% 44.4% 42.9% N/A N/A N/A N/A N/A Number -69.3% 4300 4550 4900 4400 2900 2250 2000 1800 1400 1350 1350 1400 1350 NJ 16.3 Share -71.1% 37.7% 37.6% 39.5% 38.6% 25.7% 19.0% 16.4% 15.1% 12.4% 11.5% 11.5% 11.6% 11.2% Number 32.8% 5950 6500 6950 6400 6300 6850 7100 6750 6800 7800 8500 N/A N/A FL 16.2 Share 5.8% 25.1% 26.1% 26.9% 26.4% 25.8% 26.2% 26.3% 26.2% 25.3% 26.8% 27.9% N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A AK 16 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A ASPE Issue Brief Page 11 2015 Age- Adult % Change: Adjusted Uninsured 2013-Q4 Drug Over- Substance Thru Most dose Death Use/ Mental Recent Rate (per Health Available State 100, 000) Hospital Stays Data 2013 Q1 2013 Q2 2013 Q3 2013 Q4 2014 Q1 2014 Q2 2014 Q3 2014 Q4 2015 Q1 2015 Q2 2015 Q3 2015 Q4 2016 Q1 Number -3.0% 1600 1900 1800 1650 1400 1650 1750 1600 N/A N/A N/A N/A N/A NC 15.8 Share -0.8% 14.5% 16.5% 15.3% 14.8% 13.7% 14.7% 15.0% 14.7% N/A N/A N/A N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A AL 15.7 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Number -4.0% 1050 1200 1300 1250 1150 1300 1300 1200 N/A N/A N/A N/A N/A SC 15.7 Share -7.9% 32.3% 33.3% 34.7% 35.2% 32.4% 34.7% 33.8% 32.4% N/A N/A N/A N/A N/A Number -71.4% 700 850 900 800 800 400 300 300 250 300 300 300 N/A WI 15.5 Share -70.9% 13.5% 14.9% 15.7% 15.4% 15.5% 6.5% 4.7% 4.8% 4.0% 4.8% 4.5% 4.5% N/A Number -71.4% 1150 1150 1200 1050 450 350 350 350 250 300 300 300 300 CO 15.4 Share -75.0% 34.3% 31.5% 32.9% 29.6% 13.2% 10.0% 9.2% 9.6% 6.9% 8.0% 7.9% 7.8% 7.4% Number -61.5% 500 550 600 650 350 250 250 250 N/A N/A N/A N/A N/A WA 14.7 Share -60.6% 10.8% 11.3% 12.4% 15.1% 8.0% 5.4% 5.6% 6.0% N/A N/A N/A N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A ID 14.2 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Number -68.8% 3700 3500 3700 3200 2050 1550 1300 1000 N/A N/A N/A N/A N/A IL 14.1 Share -73.7% 19.3% 18.3% 19.1% 17.8% 11.1% 7.5% 5.7% 4.7% N/A N/A N/A N/A N/A Number -58.3% 700 800 900 600 400 350 250 250 N/A N/A N/A N/A N/A AR 13.8 Share -58.3% 20.6% 22.5% 22.8% 16.9% 10.7% 9.0% 6.1% 7.0% N/A N/A N/A N/A N/A Number -20.0% 200 200 250 250 200 200 200 200 N/A N/A N/A N/A N/A MT 13.8 Share -20.0% 20.0% 20.0% 22.7% 21.7% 18.2% 17.4% 16.7% 17.4% N/A N/A N/A N/A N/A Number -10.4% 2750 2950 3000 3350 3050 2350 2150 1700 1400 1950 2350 2750 3000 NY 13.6 Share -10.6% 7.9% 8.0% 8.0% 9.3% 8.7% 6.4% 5.7% 4.7% 4.0% 5.1% 6.2% 7.8% 8.3% Number -8.7% 1050 1150 1350 1150 1050 1100 1150 1100 950 1150 1350 1600 1050 GA 12.7 Share -14.5% 16.8% 18.0% 19.9% 19.7% 17.5% 18.0% 18.0% 18.5% 16.0% 18.0% 20.6% 24.2% 16.8% Number 16.7% 2050 2100 2350 2100 2100 2250 2500 2150 2100 2300 2450 N/A N/A VA 12.4 Share -2.3% 26.8% 25.8% 28.3% 27.1% 26.6% 26.6% 27.6% 24.6% 23.9% 25.1% 26.5% N/A N/A Number N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A MS 12.3 Share N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Number -83.3% 450 600 650 600 200 100 150 100 100 100 100 100 N/A OR 12 Share -86.4% 19.6% 23.1% 22.8% 22.6% 7.3% 3.3% 4.8% 3.1% 3.3% 3.1% 3.1% 3.1% N/A ASPE Issue Brief Page 12 2015 Age- Adult % Change: Adjusted Uninsured 2013-Q4 Drug Over- Substance Thru Most dose Death Use/ Mental Recent Rate (per Health Available State 100, 000) Hospital Stays Data 2013 Q1 2013 Q2 2013 Q3 2013 Q4 2014 Q1 2014 Q2 2014 Q3 2014 Q4 2015 Q1 2015 Q2 2015 Q3 2015 Q4 2016 Q1 Number N/A 800 850 950 700 750 800 650 600 N/A N/A N/A N/A N/A KS 11.8 Share N/A 27.1% 27.9% 27.1% 23.3% 25.4% 24.6% 21.0% 21.8% N/A N/A N/A N/A N/A Number -82.1% 6850 7250 7600 7250 3150 2450 1900 1750 1500 1400 1450 1300 N/A CA 11.3 Share -83.6% 23.2% 23.5% 24.2% 25.0% 10.6% 7.7% 5.8% 5.6% 4.9% 4.4% 4.5% 4.1% N/A Number -50.0% 50 50 50 100 50 50 50 50 50 50 50 N/A N/A HI 11.3 Share -52.2% 6.7% 5.9% 5.6% 9.1% 4.5% 4.2% 4.0% 4.5% 4.5% 4.8% 4.3% N/A N/A Number -20.0% 250 250 300 250 300 300 250 200 200 150 200 N/A N/A MN 10.6 Share -23.6% 3.4% 3.2% 3.8% 3.4% 3.9% 3.7% 3.1% 2.5% 2.7% 1.9% 2.6% N/A N/A Number -75.0% 250 250 250 200 100 100 100 100 50 50 50 50 50 IA 10.3 Share -84.5% 25.0% 25.0% 22.7% 22.2% 10.0% 9.1% 8.3% 8.7% 4.5% 4.2% 4.0% 3.4% 3.4% Number 30.7% 3650 4100 4250 3750 3750 4000 4450 4100 4050 4500 4900 N/A N/A TX 9.4 Share 10.7% 24.2% 26.1% 26.6% 25.6% 25.1% 25.2% 26.6% 25.9% 25.6% 26.9% 28.3% N/A N/A Number N/A N/A N/A N/A N/A 50 100 100 100 N/A N/A N/A N/A N/A ND 8.6 Share N/A N/A N/A N/A N/A 6.7% 11.1% 11.1% 10.5% N/A N/A N/A N/A N/A Number 0.0% 100 100 100 100 100 100 100 100 100 100 50 100 N/A SD 8.4 Share -7.7% 9.1% 8.7% 8.0% 8.3% 8.3% 7.7% 8.3% 7.1% 8.0% 7.4% 4.0% 7.7% N/A Number -28.6% 350 350 400 350 500 550 500 250 N/A N/A N/A N/A N/A NE 6.9 Share -41.7% 21.2% 20.6% 22.2% 22.6% 25.0% 26.2% 23.3% 13.2% N/A N/A N/A N/A N/A ASPE Issue Brief Page 13 1 Press release: “HHS takes strong steps to address opioid-drug related overdose, death and dependence.” Retrieved from https://www.hhs.gov/about/news/2015/03/26/hhs-takes-strong-steps-to-address-opioid-drug-related-overdose- death-and-dependence.html 2 Uberoi et al., March 3, 2016. Health Insurance and the Affordable Care Act, 2010-2016. Retrieved from https://aspe.hhs.gov/sites/default/files/pdf/187551/ACA2010-2016.pdf 3 Statement by Secretary Burwell on the Uninsured Rate, September 7, 2016. https://www.hhs.gov/about/news/2016/09/07/statement-by-secretary-burwell-on-the-uninsured-rate.html 4 HCUP Fast Stats. Healthcare Cost and Utilization Project (HCUP). October 2016. Agency for Healthcare Research and Quality, Rockville, MD. https://www.hcup-us.ahrq.gov/faststats/statepayer/states.jsp 5 Dey et al., March 28, 2016. Benefits of Medicaid Expansion for Behavioral Health. Retrieved from .https://aspe.hhs.gov/sites/default/files/pdf/190506/BHMedicaidExpansion.pdf 6 January 5, 2016. Health Insurance Coverage for Americans with Pre-Existing Conditions: The Impact of the Affordable Care Act. Retrieved from https://aspe.hhs.gov/sites/default/files/pdf/255396/Pre-ExistingConditions.pdf 7 National Conference of State Legislators. Individual Health Insurance and States: Chronologies of Change. Retrieved from http://www.ncsl.org/research/health/individual-health-insurance-in-the-states.aspx 8 National Conference of State Legislators. Individual Health Insurance and States: Chronologies of Change. Retrieved from http://www.ncsl.org/research/health/individual-health-insurance-in-the-states.aspx 9 Park-Lee et al., September 2016. Receipt of services for Substance Use and Mental Health Issues among Adults: Results from the 2015 National Survey on Drug Use and Health. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-ServiceUseAdult-2015/NSDUH-ServiceUseAdult- 2015/NSDUH-ServiceUseAdult-2015.htm 10 Saloner et al., June 1 2016. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. Psychiatr Serv, 67(6): 676-9. doi: 10.1176/appi.ps.201500228. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=26927578 11 Press release: “HHS takes strong steps to address opioid-drug related overdose, death and dependence.” Retrieved from https://www.hhs.gov/about/news/2015/03/26/hhs-takes-strong-steps-to-address-opioid-drug-related-overdose- death-and-dependence.html 12 Press release: “HHS announces new actions to combat opioid epidemic.” Retrieved from https://www.hhs.gov/about/news/2016/07/06/hhs-announces-new-actions-combat-opioid-epidemic.html 13 Press release: “HHS takes additional steps to expand access to opioid treatment. Retrieved from https://www.hhs.gov/about/news/2016/11/16/additional-steps-expand-opioid-treatment.html 14 Baicker & Finkelstein, 2011. The Effects of Medicaid Coverage – Learning from the Oregon Experiment. N Engl J Med, 365:683-685. doi: 10.1056/NEJMp1108222. Retrieved from http://www.nejm.org/doi/full/10.1056/NEJMp1108222 15 Sommers et al., July 28, 2015. Changes in Self-reported Insurance Coverage, Access to Care, and Health Under the Affordable Care Act. JAMA, 314(4): 366-74. doi: 10.1001/jama.2015.8421. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=26219054 16 Savant et al., January 1, 2013. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend, 127(1-3): 243-7. doi: 10.1016/j.drugalcdep.2012.06.020. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=22771144 17 Barry et al., October 2016. Psychiatric disorders among patients seeking treatment for co-occurring chronic pain and opioid use disorder. J Clin Psychiatry, 77(10): 1413-9. doi: 10.4088/JCP.15m09963. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=27574837 18 Weist et al. Nov-Dec 2014. Pain and emotional distress among substance-use patients beginning treatment relative to a representative comparison group. J Addict Med, 8(6): 407-14. doi: 10.1097/ADM.0000000000000072. Retrieved from .https://www.ncbi.nlm.nih.gov/pubmed/?term=25275876 19 The Economic Record of the Obama Administration: Reforming the Health Care System. December 2016. Retrieved from https://www.whitehouse.gov/sites/default/files/page/files/20161213_cea_record_healh_care_reform.pdf 20 Wen et al., December 2015.Effect of Medicaid expansions on health insurance coverage and access to care among low- income adults with behavioral health conditions. Health Serv Res, 50(6): 1787-809. doi: 10.1111/1475-6773.12411. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26551430 21 Wen et al., December 2015.Effect of Medicaid expansions on health insurance coverage and access to care among low- income adults with behavioral health conditions. Health Serv Res, 50(6): 1787-809. doi: 10.1111/1475-6773.12411. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26551430 22 Ohio Medicaid Group VIII Assessment: A Report to the Ohio General Assembly. Retrieved from http://medicaid.ohio.gov/Portals/0/Resources/Reports/Annual/Group-VIII-Assessment.pdf January 11, 2017 ASPE Issue Brief Page 14 23 Foundation for a Healthy Kentucky, December 28, 2016. Substance Use Treatment Services Covered by Medicaid Expansion Jumped 740 Percent over 2.5 Years. Retrieved from https://www.healthy-ky.org/newsroom/news- releases/article/60/substance-use-treatment-services-covered-by-medicaid-expansion-jumped-740-percent-over-2.5-years? 24 Wen et al., December 2013. State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation. JAMA Psychiatry, 70(12): 1355-62. doi: 10.1001/jamapsychiatry.2013.2169. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24154931 25 Wen et al., December 2013. State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation. JAMA Psychiatry, 70(12): 1355-62. doi: 10.1001/jamapsychiatry.2013.2169. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24154931 26 Wen et al., December 2013. State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation. JAMA Psychiatry, 70(12): 1355-62. doi: 10.1001/jamapsychiatry.2013.2169. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24154931 27 Report to the Vermont State Legislature: The Effectiveness of Vermont’s System of Opioid Addiction Treatment. January 15, 2015. Retrieved from http://legislature.vermont.gov/assets/Legislative-Reports/Opioid-system-effectiveness- 1.14.15.pdf 28 Blumberg et al., December 6, 2016. Implications of Partial Repeal of the ACA through Reconciliation. Retrieved from http://www.urban.org/research/publication/implications-partial-repeal-aca-through-reconciliation 29 Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention, December 16, 2016. Drug Overdose Death Data. Retrieved from https://www.cdc.gov/drugoverdose/data/statedeaths.html January 11, 2017